Last reviewed · How we verify
Varicella vaccine live
A live attenuated varicella-zoster virus vaccine that stimulates the immune system to produce antibodies and cell-mediated immunity against varicella (chickenpox).
A live attenuated varicella-zoster virus vaccine that stimulates the immune system to produce antibodies and cell-mediated immunity against varicella (chickenpox). Used for Prevention of varicella (chickenpox) in susceptible individuals, Prevention of herpes zoster (shingles) in vaccinated individuals.
At a glance
| Generic name | Varicella vaccine live |
|---|---|
| Also known as | VARIPED®, ONVARA® |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Live attenuated vaccine |
| Target | Varicella-zoster virus (VZV) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains a weakened live strain of varicella-zoster virus (VZV) that replicates in the body without causing disease in immunocompetent individuals. This replication triggers both humoral (antibody) and cellular immune responses, providing protection against natural varicella infection and reducing the risk of herpes zoster (shingles) later in life.
Approved indications
- Prevention of varicella (chickenpox) in susceptible individuals
- Prevention of herpes zoster (shingles) in vaccinated individuals
Common side effects
- Injection site reactions (erythema, swelling, pain)
- Fever
- Varicella-like rash (vaccine strain)
- Myalgia
Key clinical trials
- Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Aged 1~12 Years: A Single-armed Bridging Clinical Trial (PHASE3)
- Second Dose of Varicella Vaccine in Healthy Children (PHASE3)
- SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years (PHASE3)
- Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine (PHASE1, PHASE2)
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept (PHASE2)
- Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Varicella vaccine live CI brief — competitive landscape report
- Varicella vaccine live updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI